Compare
Alkermes plc. vs Phibro Animal Health Corp vs PTC Therapeutics, Inc. vs Indivior Pharmaceuticals, Inc.
| Latest fiscal year | Alkermes plc. ALKS | Phibro Animal Health Corp PAHC | PTC Therapeutics, Inc. PTCT | Indivior Pharmaceuticals, Inc. INDV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.48B | $1.52B | $1.73B | $1.24B |
| Revenue growth (YoY) | -5.2% | +17.1% | +114.5% | +4.3% |
| Gross margin | 86.7% (computed) | 33.8% | n/a | 80.2% |
| Operating margin | 17.2% | 12.8% | 50.1% | 21.1% |
| Net margin | 16.4% | 6.6% | 39.4% | 16.9% |
| Net income | $241.66M | $99.72M | $682.64M | $210.00M |
| EPS (Diluted) | $1.43 | $2.43 | $7.78 | $1.64 |
| Operating cash flow | $520.75M | $68.95M | $711.20M | -$27.00M |
| Free cash flow | $480.33M | $9.87M | $702.34M | -$93.00M |
| Cash & equivalents | $388.57M | $61.42M | $984.65M | $195.00M |
| Total assets | $2.49B | $1.50B | $2.90B | $1.20B |
| Total liabilities | $667.70M | $1.12B | $3.10B | $1.30B |
| Shareholders' equity | $1.82B | $385.48M | -$205.31M | -$98.00M |
| Return on year-end equity | 13.3% | 25.9% | n/a | n/a |
| Shares outstanding | 165.61M | n/a | 81.47M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Alkermes plc. | Phibro Animal Health Corp | PTC Therapeutics, Inc. | Indivior Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $1.48B Ended 2025-12-31 | $1.52B Ended 2026-06-30 | $1.73B Ended 2025-12-31 | $1.24B Ended 2025-12-31 |
| 1 year earlier | $1.56B Ended 2024-12-31 | $1.30B Ended 2025-06-30 | $806.78M Ended 2024-12-31 | $1.19B Ended 2024-12-31 |
| 2 years earlier | $1.66B Ended 2023-12-31 | $1.02B Ended 2024-06-30 | $937.82M Ended 2023-12-31 | $1.09B Ended 2023-12-31 |
| 3 years earlier | $1.11B Ended 2022-12-31 | $977.89M Ended 2023-06-30 | $698.80M Ended 2022-12-31 | $901.00M Ended 2022-12-31 |
| 4 years earlier | $1.17B Ended 2021-12-31 | $942.26M Ended 2022-06-30 | $538.59M Ended 2021-12-31 | n/a |